Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biotricity Inc (NQ: BTCY )

0.8200 -0.0160 (-1.91%)
Streaming Delayed Price Updated: 11:12 AM EDT, Jul 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biotricity Inc

< Previous 1 2 3 4 5 6 7 Next >
Earnings Scheduled For February 20, 2024
Companies Reporting Before The Bell • Barclays (NYSE:BCS) is likely to report quarterly earnings at $0.36 per share on revenue of $7.38 billion. 
Via Benzinga
Biotricity's Earnings Outlook
Via Benzinga
Biotricity to Host Third Quarter Fiscal Year 2024 Financial Results and Business Update Call on February 21st
Via ACCESSWIRE
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Biotricity Advances Towards Breakeven Milestone - Set to Announce Record Margins and Operational Efficiency for Third Quarter of Fiscal Year 2024
Via ACCESSWIRE
Biotricity Expands Development of its Cardiac AI Cloud Platform with Data Ecosystem of over 360 billion Heartbeats
Via ACCESSWIRE
Biotricity Delivers Record Margins and Double Digit Year-Over-Year Sales Growth for Second Quarter of Fiscal Year 2024
Via ACCESSWIRE
Earnings Outlook For Biotricity
Via Benzinga
Biotricity to Host Second Quarter Fiscal Year 2024 Financial Results and Business Update Call on November 14th
Via ACCESSWIRE
CORRECTION BY SOURCE: Biotricity Announces Patent Filing for Cutting-Edge Biotres Device
Via ACCESSWIRE
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time for another dive into the biggest pre-market stock movers as we break down all of the latest news for Tuesday morning. 
Via InvestorPlace
Biotricity Releases Another Groundbreaking Product: Biotres Pro
Via ACCESSWIRE
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Biotricity Unveils a New Digital Presence, Highlighting its Expanding Technology Portfolio and Cutting-Edge Innovations
Via ACCESSWIRE
Biotricity Achieves $14 Million Revenue Run Rate in August 2023
Via ACCESSWIRE
Biotricity Shows Continued Growth and Strength in its Fundamentals on its Path to Profitability
Via ACCESSWIRE
Why Barnes Group Shares Are Trading Lower By Around 28%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Apollomics, Inc. (NASDAQ: APLM) shares surged 88.4% to $1.07 stoma multiforme with PTPRZ-MET fusion. 
Via Benzinga
Biotricity Continues to Expand Patent Portfolio with Latest Patent Filing for Bioheart Device
Via ACCESSWIRE
Biotricity Reports Strong Start to Fiscal Year 2024
Via ACCESSWIRE
Biotricity Predicted To Achieve 44% Annual Growth Despite Market Risks, Analyst Says
H.C. 
Via Benzinga
Biotricity Announces Patient Filing for Cutting-Edge Biotres Device
Via ACCESSWIRE
Biotricity Reports Strong Growth for its First Quarter Fiscal Year 2024 and Provides Financial Results and Business Updates
Via ACCESSWIRE
Biotricity to Host First Quarter Fiscal Year 2024 Financial Results and Business Update Call on August 15th
Via ACCESSWIRE
Biotricity Is Paving The Way For Cardiac Health In The Age Of AI Technology
Via ACCESSWIRE
Biotricity Is Paving The Way For Cardiac Health In The Age Of AI Technology
The integration of AI technology in healthcare has revolutionized the industry, particularly in the areas of automation, big data analytics, and optimization. AI-powered software is designed to assist... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Biotricity Expands Its Proprietary AI Model and Deepens Relationship with Amazon AWS and Google's Tensor Flow for Remote Cardiac Care Applications
Via ACCESSWIRE
Biotricity Regains Nasdaq Listing Compliance
Via ACCESSWIRE
Why 1847 Holdings Shares Are Trading Lower By Around 31%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Allarity Therapeutics, Inc. (NASDAQ: ALLR) shares surged 87% to $11.78 after the company said the initial data from Phase 2 trial of Ixempra shows potential for improved clinical benefit in... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.